List view / Grid view
3 July 2015 | By Victoria White
A study has found that it may be possible to predict early which rheumatoid arthritis patients will fail to respond to the biologic drugs given to them...
3 July 2015 | By Victoria White
The FDA has accepted for review Pfizer’s new drug application (NDA) for Xeljanz (tofacitinib citrate) 11 mg once daily modified release tablets...
1 July 2015 | By Victoria White
Teva and Xenon have reported top line results from a Phase 2b study designed to evaluate the safety and efficacy of TV-45070 in patients with osteoarthritis...
29 June 2015 | By Victoria White
New one year results from the pivotal Phase III FUTURE 2 study of Novartis’ secukinumab in psoriatic arthritis (PsA) have been published.
15 June 2015 | By Victoria White
UCB has announced data from a Phase 3 study that showed the substantial benefits, at 52 weeks, of adding Cimzia to optimised methotrexate treatment...
10 June 2015 | By Victoria White
MSD has announced additional data from a subanalysis of the GO-AHEAD study on the effect of Simponi in treating patients with nr-axial SpA...
10 June 2015 | By Victoria White
Bristol-Myers Squibb has announced that data from the Orencia Phase 3b AVERT and AMPLE trials will be presented in during the EULAR 2015...
10 June 2015 | By Victoria White
Data presented at EULAR 2015 show that the effectiveness of Celltrion’s biosimilar infliximab was similar to the RMP in rheumatoid arthritis...
9 June 2015 | By Victoria White
Carbylan Therapeutics has completed enrollment of its COR1.1 Phase 3 pivotal trial of Hydros-TA for the treatment of pain associated with osteoarthritis...
4 June 2015 | By Victoria White
UK patients with rheumatoid arthritis now have more choice for managing their condition with the launch of the ClickJect Pre-Filled pen...
2 June 2015 | By Victoria White
The rheumatoid arthritis therapeutics market in the Asia-Pacific (APAC) region will expand in value from $5.6 billion in 2014 to an estimated $7 billion by 2021, at a moderate Compound Annual Growth Rate (CAGR) of 3.3%, according to business intelligence provider GBI Research.
28 May 2015 | By Victoria White
Pfizer has announced initial results of its global NarRAtive survey of more than 3,600 adults with rheumatoid arthritis in 13 countries...
21 May 2015 | By Victoria White
Phase 3 study of sarilumab met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis...
5 May 2015 | By Victoria White
Clazakizumab has met its primary endpoint in a follow-on Phase 2b clinical trial in adults with moderate to severe rheumatoid arthritis...
27 April 2015 | By Victoria White
CHMP has adopted a positive opinion, approving BMS’ ClickJect Pre-Filled Pen for use in adult patients with moderate to severe active rheumatoid arthritis...
